The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -108,025 |
| Depreciation | 36,072 |
| Amortization of intangibles | 31,752 |
| Stock-based compensation | 41,316 |
| Non-cash operating lease expense | 6,752 |
| Amortization of convertible debt discount | 1,910 |
| Amortization of debt issuance costs | 87 |
| Loss (gain) on disposal of assets, net | -31 |
| Impairment charges (note 3 and note 7) | 27,753 |
| Impairment of long-lived assets | 0 |
| Other adjustments | -323 |
| Accounts receivable, net | 6,178 |
| Inventories | 1,543 |
| Prepaid and other assets | -1,555 |
| Operating lease liabilities | -2,215 |
| Deferred income tax liabilities, net | 3,359 |
| Accrued compensation | -15,665 |
| Accounts payable, accrued and other liabilities | -4,690 |
| Net cash provided by (used in) operating activities | 5,230 |
| Purchases of marketable securities | 0 |
| Proceeds from maturities of marketable securities | 20,060 |
| Purchases of property and equipment | 27,008 |
| Proceeds from assets held for sale, net of closing costs | 2,066 |
| Business acquisitions, net of cash acquired | 6,454 |
| Purchase of convertible note | 500 |
| Purchase of equity securities | 500 |
| Net cash (used in) provided by investing activities | -12,336 |
| Repayment of equipment financing obligations | 0 |
| Issuance of common stock, net | 962 |
| Repayment of convertible debt | 201,250 |
| Net cash (used in) provided by financing activities | -200,288 |
| Net change in cash and cash equivalents | -207,394 |
| Cash and cash equivalents at beginning of period | 367,012 |
| Cash and cash equivalents at end of period | 159,618 |
NEOGENOMICS INC (NEO)
NEOGENOMICS INC (NEO)